RedHill Biopharma
8045 Arco Corporate Drive
Suite 200
Raleigh
NC
27617
United States
Website: http://www.redhillbio.com/
477 articles about RedHill Biopharma
-
RedHill Announces New USPTO Patent Covering Talicia® Through 2034
3/11/2024
RedHill Biopharma Ltd., a specialty biopharmaceutical company, announced the issue of a new U.S. patent covering Talicia1 as an all-in-one fixed-dose combination of amoxicillin, omeprazole and rifabutin and its use for the treatment of helicobacter pylori infection.
-
RedHill's Opaganib Selected for Evaluation by BARDA and NIH Countermeasures Programs
3/5/2024
RedHill Biopharma Ltd. together with its partner Apogee Biotechnology Corporation, announced that opaganib[2] has been selected by the U.S. government's Chemical Medical Countermeasures Program and Chemical Countermeasures Research Program for evaluation as a potential medical countermeasure against inhalation Sulfur Mustard exposure.
-
RedHill's Opaganib Protects Against Radiation-Induced Lung Inflammation and Fibrosis - New Publication
2/20/2024
RedHill Biopharma Ltd., a specialty biopharmaceutical company, announced a new publication of data from multiple experiments in the International Journal of Molecular Sciences.
-
RedHill Biopharma Announces Closing of $8 Million Registered Direct Offering
1/26/2024
RedHill Biopharma Ltd. announced that it has closed its previously announced registered direct offering for the purchase and sale of 10,000,000 of the Company's American Depositary Shares, each ADS representing four hundred ordinary shares, at a purchase price of $0.80 per ADS.
-
RedHill Biopharma Announces $8 Million Registered Direct Offering
1/25/2024
RedHill Biopharma Ltd. investors for the purchase and sale of 10,000,000 of the Company's American Depositary Shares ("ADSs") at a purchase price of $0.80 per ADS, in a registered direct offering.
-
RedHill Announces New USPTO Patent Grant for Talicia® for H. pylori Treatment Through 2042
1/25/2024
RedHill Biopharma Ltd. announced that the U.S. Patent and Trademark Office issued a new patent, U.S. Patent No. 11,878,011, covering Talicia as a method for eradicating Helicobacter pylori regardless of patient Body Mass Index.
-
RedHill Biopharma Regains Compliance with Nasdaq Minimum Bid Price Requirement - December 12, 2023
12/12/2023
RedHill Biopharma Ltd. today announced that it received confirmation from The Nasdaq Stock Market LLC ("Nasdaq") that it had regained compliance with the minimum bid price requirement under Nasdaq Listing Rule 5450(a)(1).
-
RedHill Announces New, Non-Dilutive External Funding of Entire RHB-107 COVID-19 300-Patient Phase 2 Study
12/4/2023
RedHill Biopharma Ltd. today announced new non-dilutive external funding, additional to the previously announced U.S. Government funding, which now covers the entirety of the RHB-107 (upamostat) arm of the ACESO PROTECT adaptive platform trial for early COVID-19 outpatient treatment.
-
RedHill Biopharma Announces FDA Grant of 5-Year U.S. Market Exclusivity for Talicia® with IP Protection Running to 2034
11/27/2023
RedHill Biopharma Ltd. (NASDAQ: RDHL) ("RedHill" or the "Company"), a specialty biopharmaceutical company, announced that the U.S. FDA (U.S. Food and Drug Administration) has granted five years' market exclusivity for Talicia.
-
RedHill Biopharma Announces the Transfer of its Listing to The Nasdaq Capital Market
11/14/2023
RedHill Biopharma Ltd., a specialty biopharmaceutical company, announced that it has received approval from the Listing Qualifications Department of The Nasdaq Stock Market LLC to transfer the listing of the American Depositary Shares to the Nasdaq Capital Market.
-
RedHill and U.S. Army Announce Opaganib's Ebola Virus Disease Survival Benefit in U.S. Army-Funded In-Vivo Study
10/3/2023
RedHill Biopharma Ltd. (Nasdaq: RDHL) ("RedHill" or the "Company"), a specialty biopharmaceutical company, today announced that novel, twice daily, oral opaganib[1], delivered a statistically significant increase in survival time when given at 150 mg/kg twice a day (BID) in a United States Army Medical Research Institute of Infectious Diseases (USAMRIID) in vivo Ebola virus study, making it the first host-directed molecule to show activity in Ebola virus disease.
-
RedHill Biopharma Announces Receipt of Nasdaq Notification Regarding Minimum Bid Price Deficiency - September 22, 2023
9/22/2023
RedHill Biopharma Ltd. announced that on September 19, 2023, it received a letter from the Listings Qualifications Department of The Nasdaq Stock Market LLC indicating that, for the thirty consecutive business days from August 7, 2023, to September 18, 2023, the bid price for the Company's American Depositary Shares had closed below the minimum $1.00 per share requirement for continued listing on The Nasdaq Global Market under Nasdaq Listing Rule 5450.
-
RedHill Announces FDA sNDA Approval for Talicia®
9/18/2023
RedHill Biopharma Ltd. (Nasdaq: RDHL) ("RedHill" or the "Company"), a specialty biopharmaceutical company, announced the U.S. Food and Drug Administration's (FDA) approval of its supplemental new drug application (sNDA) for Talicia[.
-
RedHill Announces New USPTO Notice of Patent Allowance for Opaganib and EU Patent Grant for RHB-102 (BEKINDA®)
9/5/2023
RedHill Biopharma Ltd., a specialty biopharmaceutical company, announced that the U.S. Patent and Trademark Office had issued a Notice of Allowance for a new opaganib patent covering sphingosine kinase 2 inhibition treatment for Ebola virus disease, supporting opaganib pro tection until October 2035.
-
RedHill Biopharma Provides H1/23 Financial Results and Operational Highlights
8/17/2023
RedHill Biopharma Ltd. (Nasdaq: RDHL) ("RedHill" or the "Company"), a specialty biopharmaceutical company, today provided first half, 2023, financial results and operational highlights.
-
RedHill Biopharma Announces Talicia Approved in the United Arab Emirates and First Commercial Order Outside the U.S.
8/1/2023
RedHill Biopharma Ltd., a specialty biopharmaceutical company, announced that its partner, Gaelan Medical LLC, a wholly owned subsidiary of the Ghassan Aboud Group, has received marketing approval from the United Arab Emirates Ministry of Health for Talicia.
-
RedHill's RHB-107 Included in U.S. Government-Supported COVID-19 Platform Trial and Cleared for Initiation by FDA
7/31/2023
RedHill Biopharma Ltd. (Nasdaq: RDHL) ("RedHill" or the "Company"), a specialty biopharmaceutical company, today announced that RHB-107 (upamostat)3 has been accepted for inclusion in the Austere environments Consortium for Enhanced Sepsis Outcomes.
-
RedHill Biopharma Announces Closing of $3.8 Million Registered Direct Offering and Warrant Exercise
7/25/2023
RedHill Biopharma Ltd. announced that it has closed its previously announced registered direct offering for the purchase and sale of 1,301,923 of the Company's American Depositary Shares, each ADS representing four hundred ordinary shares, at a purchase price of $1.35 per ADS.
-
RedHill Biopharma Announces Registered Direct Offering and Warrant Exercise for $3.8 Million Gross Proceeds
7/21/2023
RedHill Biopharma Ltd. today announced that it has entered into definitive agreements with institutional investors for the purchase and sale of 1,301,923 of the Company's American Depositary Shares ("ADSs") (or ADS equivalents), each ADS representing four hundred (400) ordinary shares, at a purchase price of $1.35 per ADS (or ADS equivalent), in a registered direct offering.
-
RedHill Announces Additional U.S. Government Funding for Opaganib Nuclear Countermeasure Development
7/21/2023
RedHill Biopharma Ltd. (Nasdaq: RDHL) ("RedHill" or the "Company"), a specialty biopharmaceutical company, today announced that opaganib[1] has been awarded a further $1.7 million in U.S. Government funding, via a Small Business Innovation Research (SBIR) grant to the Company's development partner, Apogee Biotechnology Corporation ("Apogee").